Literature DB >> 16598555

[The importance of cholesterol-lowering in patients after coronary artery bypass surgery].

E von Hodenberg1, Th Breidenbach, J Melichercik.   

Abstract

Patients with aortocoronary bypass surgery generally have a severe, advanced coronary atherosclerosis. An intensive risk-factor management should be of special importance in these patients. However, cholesterol treatment goals are the same for operated or non-operated patients with coronary artery disease. Effective cholesterol lowering does not only decrease the progression of atherosclerosis in native coronary vessels but also helps to prevent the development of atherosclerosis in venous bypass grafts. Clinical studies demonstrated that this leads to an improvement of clinical endpoints. Unfortunately we know from registries, that even in bypass patients recommended guidelines for cholesterol lowering are often not followed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598555     DOI: 10.1007/s00392-006-1116-x

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  26 in total

1.  Effects of cerivastatin on vascular function of human radial and left internal thoracic arteries.

Authors:  Koki Nakamura; Sharif Al-Ruzzeh; Adrian H Chester; Ilona Schmidt; Mahmoud Barbir; Magdi H Yacoub; Mohamed Amrani
Journal:  Ann Thorac Surg       Date:  2002-06       Impact factor: 4.330

2.  The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery.

Authors:  L Campeau; M Enjalbert; J Lespérance; M G Bourassa; P Kwiterovich; S Wacholder; A Sniderman
Journal:  N Engl J Med       Date:  1984-11-22       Impact factor: 91.245

3.  Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.

Authors:  L Campeau; D B Hunninghake; G L Knatterud; C W White; M Domanski; S A Forman; J S Forrester; N L Geller; F L Gobel; J A Herd; B J Hoogwerf; Y Rosenberg
Journal:  Circulation       Date:  1999-06-29       Impact factor: 29.690

4.  Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme.

Authors: 
Journal:  Eur Heart J       Date:  2001-04       Impact factor: 29.983

5.  Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.

Authors:  Claude Gagné; Harold E Bays; Stuart R Weiss; Pedro Mata; Katherine Quinto; Michael Melino; Meehyung Cho; Thomas A Musliner; Barry Gumbiner
Journal:  Am J Cardiol       Date:  2002-11-15       Impact factor: 2.778

6.  Inhibition of intestinal cholesterol absorption by ezetimibe in humans.

Authors:  Thomas Sudhop; Dieter Lütjohann; Annette Kodal; Michael Igel; Diane L Tribble; Sukrut Shah; Inna Perevozskaya; Klaus von Bergmann
Journal:  Circulation       Date:  2002-10-08       Impact factor: 29.690

7.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28

8.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

9.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  1 in total

1.  Long-term results of a three-week intensive cardiac out-patient rehabilitation program in motivated patients with low social status.

Authors:  B Bjarnason-Wehrens; D Bott; L Benesch; K O Bischoff; B Buran-Kilian; D Gysan; U Hollenstein; W Mayer-Berger; R Wilkniss; G Sauer
Journal:  Clin Res Cardiol       Date:  2006-12-14       Impact factor: 5.460

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.